logo

For the Inventor, By the Inventor

Tokyo, Japan

Takashi Yusa

This inventor holds 4 USPTO granted patents. Top assignee: Sankyo Company, Limited. Active years: 1976-1977.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Yusa. Retrieved from https://idiyas.com/inventor/takashi-yusa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 100.0

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:

goldMedal4 out of 613 
 
Sankyo Company, Limited
 patents

Years Active: 1976-1977

Loading Chart...
4 patents (USPTO):Explore Patents
1. 4012429 - 16,16-Dimethyl (1977-03-15),
2. 3996263 - 9-Oxo-11.alpha.-methyl-15.EPSILON.-hyroxyprost-13(trans)-enoic acid (1976-12-07),
3. 3983152 - 9-Oxo-11.alpha.-hydroxymethyl-15.epsilon.-hydroxyprost-13(trans)-enoic (1976-09-28),
4. 3971825 - Pharmaceutically useful prostenoic acid derivatives (1976-07-27),

Title: Takashi Yusa: Innovator in Pharmaceutical Chemistry

Introduction

Takashi Yusa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of prostanoic acid derivatives. With a total of 4 patents to his name, Yusa's work has implications for various medical applications.

Latest Patents

Yusa's latest patents include innovative compounds such as 16,16-Dimethyl-Prostanoic acid derivatives. These compounds are characterized by a specific formula where A represents a straight or branched alkylene group with one to five carbon atoms. R¹ is a straight or branched alkyl group with four to ten carbon atoms, while R² can be a hydrogen atom or an alkyl group with one to six carbon atoms. These compounds are recognized for their utility as oxytocic agents and agents that inhibit gastric acid secretion. Another notable patent involves 9-Oxo-11.alpha.-methyl-15.EPSILON.-hydroxyprost-13(trans)-enoic acid, which serves as an anti-ulcerogenic agent.

Career Highlights

Takashi Yusa is currently associated with Sankyo Company, Limited, where he continues to advance his research in pharmaceutical innovations. His work has been instrumental in developing new therapeutic agents that address critical health issues.

Collaborations

Yusa has collaborated with notable coworkers such as Kiyoshi Sakai and Mitsuo Yamazaki, contributing to a dynamic research environment that fosters innovation.

Conclusion

Takashi Yusa's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to impact medical science positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…